HemaSphere
(Aug 2023)
P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
- Frida Bugge Askeland,
- Einar Haukås,
- Tobias S. Slørdahl,
- Anja Klostergaard,
- Tatjana Alexandersen,
- Diana Schjøll,
- Anna Lysén,
- Emil Hermansen,
- Fredrik Schjesvold
Affiliations
- Frida Bugge Askeland
- 1 Oslo Myeloma Center, Oslo University Hospital, Department of Hematology, Oslo, Norway
- Einar Haukås
- 3 Stavanger University Hospital, Department of Cancer and Blood Diseases, Stavanger, Norway
- Tobias S. Slørdahl
- 4 St. Olavs Hospital, Department of Hematology, Oslo, Norway
- Anja Klostergaard
- 5 Aarhus University Hospital, Department of Hematology, Denmark
- Tatjana Alexandersen
- 1 Oslo Myeloma Center, Oslo University Hospital, Department of Hematology, Oslo, Norway
- Diana Schjøll
- 1 Oslo Myeloma Center, Oslo University Hospital, Department of Hematology, Oslo, Norway
- Anna Lysén
- 1 Oslo Myeloma Center, Oslo University Hospital, Department of Hematology, Oslo, Norway
- Emil Hermansen
- 6 Copenhagen University Hospital, Rigshospitalet, Department of Hematology, Copenhagen, Denmark
- Fredrik Schjesvold
- 1 Oslo Myeloma Center, Oslo University Hospital, Department of Hematology, Oslo, Norway
- DOI
-
https://doi.org/10.1097/01.HS9.0000970404.32161.f4
- Journal volume & issue
-
Vol. 7
p.
e32161f4
WeChat QR code